# US 2015/0174096 A1 · Topical ophthalmological pharmaceutical composition containing sunitinib

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0174096 A1
- Document ID: US20150174096A1
- Status: Published application
- Kind: A1
- Application number: 14/408,167
- Filed: 2013-06-10
- Published: 2015-06-25
- Earliest claimed: 2012-06-12
- Assignees: Bayer HealthCare LLC
- Applicants: Bayer Healthcare LLC
- Inventors: Michael Bottger; Georges Von Degenfeld; Julia Freundlieb; Claudia Hirth-Dietrich; Joerg Keldenich; Jurgen Klar; Uwe Muenster; Andreas Ohm; Annett Richter; Bernd Riedl; Joachim Telser
- Web page: https://patentgrep.com/patent/US20150174096A1

## CPC

- A61K 31/404: Indoles, e.g. pindolol
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 47/06: Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 27/12: for cataracts
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 9/10: Dispersions; Emulsions
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to topical ophthalmological pharmaceutical compositions containing sunitinib, a hydrate, solvate or pharmaceutically acceptable salt thereof or a polymorph thereof and its process of preparation and its use for treating ophthalmological disorders.

## Claims

### Claim 1

A topical ophthalmological pharmaceutical composition comprising sunitinib, a hydrate, solvate or pharmaceutically acceptable salt of sunitinib, or a polymorph thereof as active agent and at least one pharmaceutically acceptable vehicle and optionally at least one pharmaceutically acceptable excipient.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1 which does not contain regorafenib, a hydrate, solvate or pharmaceutically acceptable salt of regorafenib or a polymorph thereof.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1 which only contains sunitinib, a hydrate, solvate or pharmaceutically acceptable salt of sunitinib or a polymorph thereof as single and only active agent and no other active agent.

### Claim 4 (depends on 1)

The pharmaceutical composition of claim 1 wherein the concentration of the active agent in the pharmaceutical composition is from 0.01 to 10% by weight of the total amount of the composition.

### Claim 5 (depends on 1)

The pharmaceutical composition of claim 1 comprising further pharmaceutically acceptable excipients like stabilizers, surfactants, polymer base carriers like gelling agents, organic co-solvents, pH active components, osmotic active components and preservatives.

### Claim 6 (depends on 1)

The pharmaceutical composition of claim 1 wherein the composition is a suspension comprising the active agent suspended in the applicable pharmaceutically acceptable vehicle.

### Claim 7 (depends on 1)

The pharmaceutical composition of claim 1 wherein the active agent is in a solid form.

### Claim 8 (depends on 1)

The pharmaceutical composition of claim 1 wherein the active agent is in a crystalline form.

### Claim 9 (depends on 1)

The pharmaceutical composition of claim 1 wherein the active agent is in a microcrystalline form.

### Claim 10 (depends on 1)

The pharmaceutical composition of claim 1 wherein the pharmaceutically acceptable vehicle is selected from the group comprising oleoyl polyethyleneglycol gylcerides, linoleoyl polyethyleneglycol gylcerides, lauroyl polyethyleneglycol gylcerides, liquid paraffin, light liquid paraffin, soft paraffin (vaseline), hard paraffin, castor oil, peanut oil, sesame oil, middle chain trigylcerides, cetylstearylalcohols, wool fat, glycerol, propylene glycol, polyethyleneglycols (PEG), water or a mixture thereof.

### Claim 11 (depends on 1)

The pharmaceutical composition of claim 1 based on a non-aqueous vehicle.

### Claim 12 (depends on 1)

The pharmaceutical composition of claim 1 based on a hydrophobic vehicle.

### Claim 13 (depends on 1)

The pharmaceutical composition of claim 1 wherein the pharmaceutically acceptable vehicle is selected from the group comprising liquid paraffin, light liquid paraffin or a mixture thereof.

### Claim 14 (depends on 1)

The pharmaceutical composition of claim 1 wherein the composition is a non-aqueous solution comprising the active agent dissolved in the non-aqueous applicable pharmaceutically acceptable vehicle.

### Claim 15 (depends on 14)

The pharmaceutical composition of claim 14 wherein the non-aqueous applicable pharmaceutically acceptable vehicle is selected from the group comprising oleoyl polyethyleneglycol gylcerides, linoleoyl polyethyleneglycol gylcerides, lauroyl polyethyleneglycol gylcerides, hydrocarbon vehicles like liquid paraffin, light liquid paraffin, soft paraffin, hard paraffin, vegetable fatty oils like castor oil, peanut oil or sesame oil, synthetic fatty oils like middle chain trigylcerides, isopropyl myristate, caprylocaproyl macrogol-8 glyceride, caprylocaproyl polyoxyl-8 glycerides, wool alcohols, wool fat, glycerol, propylene glycol, propylene glycol diesters of caprylic/capric acid, polyethyleneglycols (PEG), semifluorinated alkanes or a mixture of thereof.

### Claim 16 (depends on 1)

A process for manufacturing a pharmaceutical composition according to claim 1 wherein the active agent is dissolved or suspended in an applicable pharmaceutically acceptable vehicle optionally in the presence of further one or more pharmaceutically acceptable excipients and the solution or suspension is homogenized.

### Claim 17 (depends on 1)

The pharmaceutical composition of claim 1 for the use of treating or preventing an ophthalmological disorder selected from the group comprising age-related macular degeneration (AMD), choroidal neovascularization (CNV), choroidal neovascular membrane (CNVM), cystoid macula edema (CME), epi-retinal membrane (ERM) and macular hole, myopia-associated choroidal neovascularisation, vascular streaks, retinal detachment, diabetic retinopathy, diabetic macular edema (DME), atrophic changes of the retinal pigment epithelium (RPE), hypertrophic changes of the retinal pigment epithelium (RPE), retinal vein occlusion, choroidal retinal vein occlusion, macular edema, macular edema due to retinal vein occlusion, retinitis pigmentosa, Stargardt's disease, glaucoma, inflammatory conditions, cataract, refractory anomalies, ceratoconus, retinopathy of prematurity, angiogenesis in the front of the eye, corneal angiogenesis following keratitis, corneal transplantation or keratoplasty, corneal angiogenesis due to hypoxia (extensive contact lens wearing), pterygium conjunctivae, subretinal edema and intraretinal edema.

### Claim 18 (depends on 1)

The pharmaceutical composition of claim 1 for the use of treating or preventing of a posterior eye disease.

### Claim 19 (depends on 1)

The pharmaceutical composition of claim 1 for the use of treating or preventing an ophthalmological disorder selected from the group comprising dry AMD, wet AMD or choroidal neovascularization (CNV).

### Claim 20 (depends on 1)

Method for treating or preventing an ophthalmological disorder selected from the group comprising age-related macular degeneration (AMD), choroidal neovascularization (CNV), choroidal neovascular membrane (CNVM), cystoid macula edema (CME), epi-retinal membrane (ERM) and macular hole, myopia-associated choroidal neovascularisation, vascular streaks, retinal detachment, diabetic retinopathy, diabetic macular edema (DME), atrophic changes of the retinal pigment epithelium (RPE), hypertrophic changes of the retinal pigment epithelium (RPE), retinal vein occlusion, choroidal retinal vein occlusion, macular edema, macular edema due to retinal vein occlusion, retinitis pigmentosa, Stargardt's disease, glaucoma, inflammatory conditions, cataract, refractory anomalies, ceratoconus, retinopathy of prematurity, angiogenesis in the front of the eye, corneal angiogenesis following keratitis, corneal transplantation or keratoplasty, corneal angiogenesis due to hypoxia (extensive contact lens wearing), pterygium conjunctivae, subretinal edema and intraretinal edema comprising administering a pharmaceutical composition according to claim 1 containing a pharmaceutically effective amount of the active agent.
